12/4
08:04 am
pvla
Palvella Therapeutics (NASDAQ:PVLA) is now covered by analysts at Craig Hallum. They set a "buy" rating on the stock.
Low
Report
Palvella Therapeutics (NASDAQ:PVLA) is now covered by analysts at Craig Hallum. They set a "buy" rating on the stock.
11/26
02:13 pm
pvla
Palvella Therapeutics (NASDAQ:PVLA) had its "sell (d)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Palvella Therapeutics (NASDAQ:PVLA) had its "sell (d)" rating reaffirmed by analysts at
Weiss Ratings.
11/24
07:19 am
pvla
Palvella Therapeutics (NASDAQ:PVLA) was given a new $145.00 price target on by analysts at Stifel Nicolaus.
Low
Report
Palvella Therapeutics (NASDAQ:PVLA) was given a new $145.00 price target on by analysts at Stifel Nicolaus.
11/19
08:07 am
pvla
Palvella Therapeutics (NASDAQ:PVLA) was upgraded by analysts at Raymond James Financial, Inc. from an "outperform" rating to a "strong-buy" rating. They now have a $143.00 price target on the stock, up previously from $92.00.
High
Report
Palvella Therapeutics (NASDAQ:PVLA) was upgraded by analysts at Raymond James Financial, Inc. from an "outperform" rating to a "strong-buy" rating. They now have a $143.00 price target on the stock, up previously from $92.00.
11/13
04:04 pm
pvla
Palvella Therapeutics (NASDAQ:PVLA) had its price target raised by analysts at Canaccord Genuity Group Inc. from $90.00 to $148.00. They now have a "buy" rating on the stock.
Medium
Report
Palvella Therapeutics (NASDAQ:PVLA) had its price target raised by analysts at Canaccord Genuity Group Inc. from $90.00 to $148.00. They now have a "buy" rating on the stock.
11/13
09:07 am
pvla
Palvella Therapeutics (NASDAQ:PVLA) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $110.00 price target on the stock.
Low
Report
Palvella Therapeutics (NASDAQ:PVLA) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $110.00 price target on the stock.
11/12
10:52 am
pvla
Palvella Therapeutics (NASDAQ:PVLA) Is In A Good Position To Deliver On Growth Plans [Yahoo! Finance]
Medium
Report
Palvella Therapeutics (NASDAQ:PVLA) Is In A Good Position To Deliver On Growth Plans [Yahoo! Finance]
11/11
06:02 pm
pvla
Palvella Therapeutics (NASDAQ:PVLA) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
Medium
Report
Palvella Therapeutics (NASDAQ:PVLA) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
11/11
04:26 pm
pvla
Palvella Therapeutics Inc (PVLA) Q3 2025 Earnings Call Highlights: Strategic Advancements and ... [Yahoo! Finance]
Low
Report
Palvella Therapeutics Inc (PVLA) Q3 2025 Earnings Call Highlights: Strategic Advancements and ... [Yahoo! Finance]
11/11
09:01 am
pvla
Palvella Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]
Low
Report
Palvella Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]
11/11
08:36 am
pvla
Palvella Therapeutics GAAP EPS of -$1.03 misses by $0.19 [Seeking Alpha]
Medium
Report
Palvella Therapeutics GAAP EPS of -$1.03 misses by $0.19 [Seeking Alpha]
11/11
07:30 am
pvla
Palvella Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Medium
Report
Palvella Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
11/10
12:06 pm
pvla
Palvella Therapeutics (NASDAQ:PVLA) had its price target raised by analysts at Truist Financial Corporation from $80.00 to $105.00. They now have a "buy" rating on the stock.
Low
Report
Palvella Therapeutics (NASDAQ:PVLA) had its price target raised by analysts at Truist Financial Corporation from $80.00 to $105.00. They now have a "buy" rating on the stock.
11/7
03:02 pm
pvla
Palvella Therapeutics (NASDAQ:PVLA) had its price target raised by analysts at Chardan Capital from $73.00 to $110.00. They now have a "buy" rating on the stock.
Low
Report
Palvella Therapeutics (NASDAQ:PVLA) had its price target raised by analysts at Chardan Capital from $73.00 to $110.00. They now have a "buy" rating on the stock.
11/6
01:29 pm
pvla
Palvella Therapeutics (NASDAQ:PVLA) had its price target raised by analysts at TD Cowen from $65.00 to $97.00. They now have a "buy" rating on the stock.
Low
Report
Palvella Therapeutics (NASDAQ:PVLA) had its price target raised by analysts at TD Cowen from $65.00 to $97.00. They now have a "buy" rating on the stock.
11/6
10:50 am
pvla
Palvella Therapeutics (NASDAQ:PVLA) had its price target raised by analysts at Cantor Fitzgerald from $120.00 to $200.00. They now have an "overweight" rating on the stock.
Low
Report
Palvella Therapeutics (NASDAQ:PVLA) had its price target raised by analysts at Cantor Fitzgerald from $120.00 to $200.00. They now have an "overweight" rating on the stock.
11/6
08:40 am
pvla
Palvella Therapeutics (NASDAQ:PVLA) had its price target raised by analysts at HC Wainwright from $95.00 to $190.00. They now have a "buy" rating on the stock.
Medium
Report
Palvella Therapeutics (NASDAQ:PVLA) had its price target raised by analysts at HC Wainwright from $95.00 to $190.00. They now have a "buy" rating on the stock.
11/6
07:30 am
pvla
Palvella Therapeutics to Present at the Stifel 2025 Healthcare Conference
Medium
Report
Palvella Therapeutics to Present at the Stifel 2025 Healthcare Conference
11/5
06:00 am
pvla
Palvella Therapeutics Announces New QTORIN™ Product Candidate, QTORIN™ Pitavastatin, for the Treatment of Disseminated Superficial Actinic Porokeratosis (DSAP), a Rare, Chronic, and Pre-Cancerous Genetic Skin Disease with No FDA-Approved Therapies
Medium
Report
Palvella Therapeutics Announces New QTORIN™ Product Candidate, QTORIN™ Pitavastatin, for the Treatment of Disseminated Superficial Actinic Porokeratosis (DSAP), a Rare, Chronic, and Pre-Cancerous Genetic Skin Disease with No FDA-Approved Therapies
11/4
07:30 am
pvla
Palvella Therapeutics to Host Third Quarter 2025 Financial Results and Corporate Update Conference Call on November 11, 2025
Low
Report
Palvella Therapeutics to Host Third Quarter 2025 Financial Results and Corporate Update Conference Call on November 11, 2025
10/17
10:06 pm
pvla
CG Oncology (CGON) Gets Initiated With a Buy at Guggenheim [Yahoo! Finance]
Medium
Report
CG Oncology (CGON) Gets Initiated With a Buy at Guggenheim [Yahoo! Finance]
10/13
10:30 am
pvla
U.S. Food and Drug Administration Awards Year Two Proceeds from Orphan Products Grant Supporting Palvella Therapeutics' Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations [Yahoo! Finance]
Low
Report
U.S. Food and Drug Administration Awards Year Two Proceeds from Orphan Products Grant Supporting Palvella Therapeutics' Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations [Yahoo! Finance]
10/13
07:30 am
pvla
U.S. Food and Drug Administration Awards Year Two Proceeds from Orphan Products Grant Supporting Palvella Therapeutics’ Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations
Medium
Report
U.S. Food and Drug Administration Awards Year Two Proceeds from Orphan Products Grant Supporting Palvella Therapeutics’ Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations
10/9
07:02 am
pvla
Palvella Therapeutics (NASDAQ:PVLA) was given a new $90.00 price target on by analysts at Canaccord Genuity Group Inc..
Medium
Report
Palvella Therapeutics (NASDAQ:PVLA) was given a new $90.00 price target on by analysts at Canaccord Genuity Group Inc..
10/7
01:02 pm
pvla
Palvella Therapeutics (NASDAQ:PVLA) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
Low
Report
Palvella Therapeutics (NASDAQ:PVLA) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.